country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-172426

Copy Link Print Information

Dirozalkib

Dirozalkib is an orally active and blood-brain barrier-penetrant ALK tyrosine kinase inhibitor. Dirozalkib inhibits the proliferation of ALK fusion-positive and ALK TKI-resistant tumor cells, and inhibits tumor growth in PDX and intracranial xenograft lung cancer models. Dirozalkib can be used for research related to non-small cell lung cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 1893419-37-8
分子式: C₂₇H₃₂ClN₅O₄S
分子量:558.09

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (292 KB)

Dirozalkib 構造式

CAS 番号: 1893419-37-8

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体外実験

Anti-cancer

Dirozalkib (72 h) inhibits proliferation of Ba/F3 cells expressing EML4-ALK and resistant ALK mutants and NCI-H3122 cells with IC₅₀ values ranging from 1.92 to 62.85 nmol/L^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Anti-cancer

Dirozalkib (24 mg/kg; p.o.; once daily; for 21 consecutive days) produces significant tumor growth inhibition in the Crizotinib (HY-50878)-resistant LU-01-0319R non-small cell lung cancer PDX model^[1].
Dirozalkib (50 mg/kg; p.o.; once daily; for 21 consecutive days) produces potent tumor growth inhibition in the LU-01-0414 non-small cell lung cancer PDX model^[1].
Dirozalkib (100 mg/kg; p.o.; once daily; 14 days) inhibits intracranial tumor growth and prolongs survival in the H2228-luc non-small cell lung cancer xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

化学情報

CAS 番号 1893419-37-8
分子量 558.09
分子式 C₂₇H₃₂ClN₅O₄S
SMILES

O=S(C1=C(NC2=NC(NC3=C4OCCOC4=C(C5CCNCC5)C(C)=C3)=NC=C2Cl)C=CC=C1)(C(C)C)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (292 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ai X, et al. Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 2026 Feb 25;235:116221.

[2]. Fang L, et al. Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib). Cancer chemotherapy and pharmacology. 2025 Dec 05;95(1):122.

[3]. Liu Y, et al. Abstract CT243: Dirozalkib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC): Results from a phase 2 study. Cancer Research. 2026 Apr 17;86(8_Supplement):CT243-.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ